At Invizius we are developing products to treat diseases driven by excessive activation of the patient's complement system.
Our first product, H-Guard® Priming Solution, is initially targeting patients with severe Acute Kidney Injury (AKI) requiring dialysis, and is designed to reduce dialysis-induced kidney damage and the transition to End Stage Renal Disease (ESRD).
Our second product (INV-201) is designed to prevent peritoneal fibrosis among ESRD patients on peritoneal dialysis, making the treatment more durable. This will improve patient outcomes, reduce healthcare costs, and increase profitability for dialysis equipment manufacturers.
We are researching a number of other therapeutic areas for further development of our PspCN complement regulation platform.
Meso-Guard™ for Peritoneal Dialysis
Download our report about the use of Meso-Guard as a potential treatment for complement dysregulation in Peritoneal Dialysis patients.
Woman's Health
Download our report on the impact of preeclampsia and the role of complement activation in preeclampsia. The potential of H-Guard Prophylactic Therapy as a therapeutic target for preventing pregnancy complications such as preeclampsia.
Neuroinflammation
Download our report on novel therapeutics that target the complement cascade to regulate inflammation in the brain, particularly in conditions such as traumatic brain injury and ischemic stroke.
H-Guard for SLE
